Year: 2023
Type: article
Abstract: Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.
Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital General Universitario Gregorio Marañón, Hospital Clínico San Carlos, Hospital Universitario Virgen de la Arrixaca, Hospital Universitario La Paz, Hospital de Basurto, Hospital de Sant Pau, Hospital Clínico Universitario Virgen de la Victoria, Hospital Universitario Fundación Jiménez Díaz
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,290
OpenAlex ID: W4367669071